Skip to Content

Lonza Group Ltd LONN Stock Quote

| Rating as of


Morningstar‘s Stock Analysis LONN

Currency in CHF
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Positive Outlook for Narrow-Moat Lonza; Maintaining CHF 620 FVE, Shares Undervalued

Rachel Elfman Equity Analyst

Analyst Note

| Rachel Elfman |

Our long-term outlook for Lonza looks bright as drug manufacturing continues to become more complex with biologics and cell and gene therapies playing larger roles. We maintain our fair value estimate of CHF 620 per share for narrow-moat Lonza. We view Lonza’s stock price as undervalued, currently trading 20% below our fair value estimate in 4-star territory.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics LONN

Company Profile LONN

Business Description

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Muenchensteinerstrasse 38
Basel, CH-4002, Switzerland
T +41 613168111
Industry Diagnostics & Research
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Employees 17,154